factors that could cause or contribute to those differences include , but are not limited to , those identified below and those discussed above in the section entitled “ 1a . risk factors . ” 18 overview our principal business is the manufacturing , distribution and marketing of physical medicine products and aesthetic products . we offer a broad line of medical equipment including therapy devices , medical supplies and soft goods , treatment tables and rehabilitation equipment . our line of aesthetic equipment includes aesthetic massage and microdermabrasion devices , as well as skin care products . our products are sold to and used primarily by physical therapists , chiropractors , sports medicine practitioners , podiatrists , plastic surgeons , dermatologists , aestheticians and other aesthetic services providers . our fiscal year ends on june 30. reference to fiscal year 2014 refers to the year ended june 30 , 2014. results of operations fiscal year 2014 compared to fiscal year 2013 net sales net sales in fiscal year 2014 were $ 27,444,223 , compared to $ 29,538,275 in fiscal year 2013. in fiscal year 2013 , we introduced the new solarisplus product line which significantly increased sales of manufactured capital devices during that period . in fiscal year 2014 , increased sales of our top-selling solarisplus therapy devices and new thermostim probe were offset by lower sales of certain medical products and supplies , including other manufactured modalities , metal treatment tables , exercise products , nutritional supplements and taping products . market conditions continued to deteriorate during the year due to the patient protection and affordable care act as amended by the health care and education reconciliation act , each enacted in march 2010 ( the “ health care reform law ” ) . the health care reform law has had the effect of creating significant uncertainty relative to delivery of care and reimbursement . there has been a marked decline in the opening of new clinics and expansion of existing clinics in our marketplace which typically are a significant source of demand for our products – particularly the higher margin capital equipment products . the uncertainty surrounding the health care reform law has not only led to customers focusing more on controlling operating costs by reducing expenditures , but has also caused a reluctance to invest in new equipment and clinic upgrades . in addition to the impacts of the health care reform law , we continue to see slower economic recovery in some parts of the country as well as a temporary decrease in demand due to severe weather events during this past winter . with a currently shrinking market , it is necessary to implement strategies to increase market share . to accomplish that , management has undertaken efforts to ( i ) expand our distribution channels by adding several new dealers and sales representatives , and ( ii ) stimulate sales of the new dynatron thermostim probe and other new products . we may also consider the acquisition of other businesses and technology . the new thermostim probe delivers thermal ( hot and cold ) therapy and or electrotherapy in a targeted , attended treatment . because the probe is operated from the control console of the solarisplus units , we are seeing demand for solarisplus units rise commensurate with the demand for the thermostim probe . management believes that as healthcare reform progresses , uncertainty in our market will diminish , and demand for our products will begin to strengthen . sales of proprietary manufactured physical medicine products represented approximately 47 % and 46 % of total physical medicine product sales in fiscal years 2014 and 2013 , respectively . distribution of products manufactured by other suppliers accounted for the balance of our physical medicine product sales in those years . sales of manufactured aesthetic products in fiscal years 2014 and 2013 , represented approximately 86 % and 78 % of total aesthetic product sales , respectively , with distributed products making up the balance . the majority of our sales revenues come from the sale of physical medicine products , both manufactured and distributed . in fiscal years 2014 and 2013 , sales of physical medicine products accounted for 91 % of total sales in both years . chargeable repairs , billable freight revenue , aesthetic product sales and other miscellaneous revenue accounted for approximately 9 % of total revenues in both years . 19 gross profit gross profit totaled $ 10,020,372 , or 36.5 % of net sales , in fiscal year 2014 , compared to $ 11,086,602 , or 37.5 % of net sales , in fiscal year 2013. lower sales revenue generated during the year was the primary factor in the reduction in gross profit compared to the prior year period . in addition , a reduction in revenue from the phasing out of our stream software service contributed to the lower gross profit and gross margin percentage generated in the reporting periods . sales of stream services were approximately $ 7,765 in 2014 , compared to $ 108,100 in 2013. those sales were 100 % gross profit as they carried no associated cost of sale . loss of approximately $ 100,000 in gross profit from the termination of the stream program accounted for one third of the drop in gross profit percentage . the balance was attributable to product mix favoring lower margin supply products and slightly increased cost of sales for manufactured capital products . story_separator_special_tag this product line consists of four units : the dynatron solarisplus 709 , 708 , 706 , and 705. these attractive units provide our most advanced technology in combination therapy devices by adding phototherapy capabilities to enhanced electrotherapy and ultrasound combination devices . the dynatron solarisplus line of products features a tri-wave phototherapy probe and a tri-wave phototherapy pad . tri-wave phototherapy features infrared , red and blue wavelength light . the dynatron solaris tri-wave phototherapy pad is capable of treating large areas of the body via unattended infrared , red and blue wavelength phototherapy . the tri-wave phototherapy probe allows the practitioner to treat specific , targeted areas of the body in an attended treatment . as part of the solarisplus product line , we also introduced a display cart specifically designed for these units . the solarisplus line has become popular for its power and versatility . the units are capable of simultaneously powering five electrotherapy channels , ultrasound therapy , a phototherapy probe and phototherapy pad . no other device on the market offers such powerful simultaneous combination therapies . 24 the introduction of so many new products in the last two years marks the most productive two year period of new product introductions in our history . with most of the planned new products now released , r & d costs in 2014 cycled back to a lower level more in line with historical amounts . management is confident the investments made in r & d will yield long-term benefits and are important to assuring that we maintain our reputation in the industry for being an innovator and leader in product development . our product catalog not only includes our proprietary products previously discussed , but also our expansive offering of non-proprietary products ( approximately 13,000 skus ) to service the broader needs of our customers . it also provides an excellent sales tool for our sales representatives in the field and the foundation for our e-commerce platform . the catalog includes an online electronic version of the catalog that is incorporated into our e-commerce website . the catalog has been praised for its clarity and ease of use . over the past few years , consolidations in our market have changed the landscape of our industry 's distribution channels . at the present time , we believe that there remain only two companies with a national direct sales force selling proprietary and distributed products : dynatronics and patterson medical . all other distribution in our market is directed through catalog companies with a limited direct sales force , or through independent local dealers that have limited geographical reach . our national direct sales force consists of direct sales employees and independent sales representatives . in addition to these direct sales representatives , we continue to enjoy a strong relationship with scores of independent dealers . we believe we have the best trained and most knowledgeable sales force in the industry . we are actively seeking to expand our market penetration through increased distribution . to accomplish this , during fiscal year 2014 , for the first time in our history , we made available to all distributors and qualified sales persons , a family of proprietary combination therapy devices , the dynatron 25 series . the availability of these products is attracting new distributors and sales persons . in addition , where these sales persons have had limited or no access to premier lines like the dynatron solarisplus products , they are now able to access these products in certain geographical areas through the authorized sales representative or dealer who has the rights to the products in those territories . making these products more widely available is expected to increase our ability to expand distribution of not only our own proprietary products , but also those we distribute on behalf of other manufacturers . pursuit of national accounts , including group purchasing organizations ( gpo ) continues to be a strategic endeavor . during fiscal year 2014 , we signed an exclusive , sole-source agreement with amerinet , one of the five largest gpo 's in the united states , to supply medical products to their acute care and alternate care members . amerinet is one of the nation 's leading healthcare gpos , helping its members to reduce healthcare costs and improve healthcare quality . the three-year agreement with amerinet became effective july 1 , 2014. the prior vendor reported approximately $ 6,000,000 per year in sales to amerinet members . we do not expect that this contract will rise to that level for various reasons and we anticipate that it will take several months to ramp up sales under this contract . we expect that sales under this contract will gradually increase over the life of the contract to a rate of approximately $ 3,000,000 annually . in 2013 , we were successful in qualifying to be an approved vendor to the federal government , including the veterans administration hospitals and medical facilities associated with military installations . economic pressures from the recent recession in the united states have affected available credit that would facilitate large capital purchases , and have also reduced demand for discretionary services such as those provided by the purchasers of our aesthetic products . as a result , we reduced our expenses in the synergie department . we believe that our aesthetic devices remain the best value on the market and we are seeking innovative ways to market these products , including strategic partnerships , both domestic and international , to help enhance sales momentum . we have long believed that international markets present an untapped potential for growth and expansion . adding new distributors in several countries will be the key to this expansion effort . we remain committed to finding the most effective ways to expand our markets internationally . over the coming year , our efforts will be focused on partnering with key manufacturers and

liquidity and capital resources we have financed operations through cash from operations , available cash reserves , and borrowings under a line of credit with a bank . working capital decreased $ 197,993 to $ 3,347,595 as of june 30 , 2014 , inclusive of the current portion of long-term obligations and credit facilities , compared to working capital of $ 3,545,588 as of june 30 , 2013. as of june 30 , 2014 , the company had approximately $ 978,800 of available credit under a credit facility with a commercial bank . the current ratio was 1.5 to 1 as of june 30 , 2014 and june 30 , 2013. current assets were 73 % of total assets as of june 30 , 2014 and 72 % of total assets as of june 30 , 2013. cash and cash equivalents our cash and cash equivalents position as of june 30 , 2014 , was $ 332,800 , compared to cash and cash equivalents of $ 302,050 as of june 30 , 2013. our cash position varies throughout the year , but typically stays within a range of $ 200,000 to $ 350,000. we expect that cash flows from operating activities , together with amounts available through an existing line-of-credit facility , will be sufficient to cover operating needs in the ordinary course of business for at least the next twelve months . if we experience an adverse operating environment , or unusual capital expenditure requirements , additional financing may be required . no assurance can be given that additional financing , if required , would be available on terms favorable to us , or at all .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we have financed operations through cash from operations , available cash reserves , and borrowings under a line of credit with a bank . working capital decreased $ 197,993 to $ 3,347,595 as of june 30 , 2014 , inclusive of the current portion of long-term obligations and credit facilities , compared to working capital of $ 3,545,588 as of june 30 , 2013. as of june 30 , 2014 , the company had approximately $ 978,800 of available credit under a credit facility with a commercial bank . the current ratio was 1.5 to 1 as of june 30 , 2014 and june 30 , 2013. current assets were 73 % of total assets as of june 30 , 2014 and 72 % of total assets as of june 30 , 2013. cash and cash equivalents our cash and cash equivalents position as of june 30 , 2014 , was $ 332,800 , compared to cash and cash equivalents of $ 302,050 as of june 30 , 2013. our cash position varies throughout the year , but typically stays within a range of $ 200,000 to $ 350,000. we expect that cash flows from operating activities , together with amounts available through an existing line-of-credit facility , will be sufficient to cover operating needs in the ordinary course of business for at least the next twelve months . if we experience an adverse operating environment , or unusual capital expenditure requirements , additional financing may be required . no assurance can be given that additional financing , if required , would be available on terms favorable to us , or at all .
```    
 Suspicious Activity Report : factors that could cause or contribute to those differences include , but are not limited to , those identified below and those discussed above in the section entitled “ 1a . risk factors . ” 18 overview our principal business is the manufacturing , distribution and marketing of physical medicine products and aesthetic products . we offer a broad line of medical equipment including therapy devices , medical supplies and soft goods , treatment tables and rehabilitation equipment . our line of aesthetic equipment includes aesthetic massage and microdermabrasion devices , as well as skin care products . our products are sold to and used primarily by physical therapists , chiropractors , sports medicine practitioners , podiatrists , plastic surgeons , dermatologists , aestheticians and other aesthetic services providers . our fiscal year ends on june 30. reference to fiscal year 2014 refers to the year ended june 30 , 2014. results of operations fiscal year 2014 compared to fiscal year 2013 net sales net sales in fiscal year 2014 were $ 27,444,223 , compared to $ 29,538,275 in fiscal year 2013. in fiscal year 2013 , we introduced the new solarisplus product line which significantly increased sales of manufactured capital devices during that period . in fiscal year 2014 , increased sales of our top-selling solarisplus therapy devices and new thermostim probe were offset by lower sales of certain medical products and supplies , including other manufactured modalities , metal treatment tables , exercise products , nutritional supplements and taping products . market conditions continued to deteriorate during the year due to the patient protection and affordable care act as amended by the health care and education reconciliation act , each enacted in march 2010 ( the “ health care reform law ” ) . the health care reform law has had the effect of creating significant uncertainty relative to delivery of care and reimbursement . there has been a marked decline in the opening of new clinics and expansion of existing clinics in our marketplace which typically are a significant source of demand for our products – particularly the higher margin capital equipment products . the uncertainty surrounding the health care reform law has not only led to customers focusing more on controlling operating costs by reducing expenditures , but has also caused a reluctance to invest in new equipment and clinic upgrades . in addition to the impacts of the health care reform law , we continue to see slower economic recovery in some parts of the country as well as a temporary decrease in demand due to severe weather events during this past winter . with a currently shrinking market , it is necessary to implement strategies to increase market share . to accomplish that , management has undertaken efforts to ( i ) expand our distribution channels by adding several new dealers and sales representatives , and ( ii ) stimulate sales of the new dynatron thermostim probe and other new products . we may also consider the acquisition of other businesses and technology . the new thermostim probe delivers thermal ( hot and cold ) therapy and or electrotherapy in a targeted , attended treatment . because the probe is operated from the control console of the solarisplus units , we are seeing demand for solarisplus units rise commensurate with the demand for the thermostim probe . management believes that as healthcare reform progresses , uncertainty in our market will diminish , and demand for our products will begin to strengthen . sales of proprietary manufactured physical medicine products represented approximately 47 % and 46 % of total physical medicine product sales in fiscal years 2014 and 2013 , respectively . distribution of products manufactured by other suppliers accounted for the balance of our physical medicine product sales in those years . sales of manufactured aesthetic products in fiscal years 2014 and 2013 , represented approximately 86 % and 78 % of total aesthetic product sales , respectively , with distributed products making up the balance . the majority of our sales revenues come from the sale of physical medicine products , both manufactured and distributed . in fiscal years 2014 and 2013 , sales of physical medicine products accounted for 91 % of total sales in both years . chargeable repairs , billable freight revenue , aesthetic product sales and other miscellaneous revenue accounted for approximately 9 % of total revenues in both years . 19 gross profit gross profit totaled $ 10,020,372 , or 36.5 % of net sales , in fiscal year 2014 , compared to $ 11,086,602 , or 37.5 % of net sales , in fiscal year 2013. lower sales revenue generated during the year was the primary factor in the reduction in gross profit compared to the prior year period . in addition , a reduction in revenue from the phasing out of our stream software service contributed to the lower gross profit and gross margin percentage generated in the reporting periods . sales of stream services were approximately $ 7,765 in 2014 , compared to $ 108,100 in 2013. those sales were 100 % gross profit as they carried no associated cost of sale . loss of approximately $ 100,000 in gross profit from the termination of the stream program accounted for one third of the drop in gross profit percentage . the balance was attributable to product mix favoring lower margin supply products and slightly increased cost of sales for manufactured capital products . story_separator_special_tag this product line consists of four units : the dynatron solarisplus 709 , 708 , 706 , and 705. these attractive units provide our most advanced technology in combination therapy devices by adding phototherapy capabilities to enhanced electrotherapy and ultrasound combination devices . the dynatron solarisplus line of products features a tri-wave phototherapy probe and a tri-wave phototherapy pad . tri-wave phototherapy features infrared , red and blue wavelength light . the dynatron solaris tri-wave phototherapy pad is capable of treating large areas of the body via unattended infrared , red and blue wavelength phototherapy . the tri-wave phototherapy probe allows the practitioner to treat specific , targeted areas of the body in an attended treatment . as part of the solarisplus product line , we also introduced a display cart specifically designed for these units . the solarisplus line has become popular for its power and versatility . the units are capable of simultaneously powering five electrotherapy channels , ultrasound therapy , a phototherapy probe and phototherapy pad . no other device on the market offers such powerful simultaneous combination therapies . 24 the introduction of so many new products in the last two years marks the most productive two year period of new product introductions in our history . with most of the planned new products now released , r & d costs in 2014 cycled back to a lower level more in line with historical amounts . management is confident the investments made in r & d will yield long-term benefits and are important to assuring that we maintain our reputation in the industry for being an innovator and leader in product development . our product catalog not only includes our proprietary products previously discussed , but also our expansive offering of non-proprietary products ( approximately 13,000 skus ) to service the broader needs of our customers . it also provides an excellent sales tool for our sales representatives in the field and the foundation for our e-commerce platform . the catalog includes an online electronic version of the catalog that is incorporated into our e-commerce website . the catalog has been praised for its clarity and ease of use . over the past few years , consolidations in our market have changed the landscape of our industry 's distribution channels . at the present time , we believe that there remain only two companies with a national direct sales force selling proprietary and distributed products : dynatronics and patterson medical . all other distribution in our market is directed through catalog companies with a limited direct sales force , or through independent local dealers that have limited geographical reach . our national direct sales force consists of direct sales employees and independent sales representatives . in addition to these direct sales representatives , we continue to enjoy a strong relationship with scores of independent dealers . we believe we have the best trained and most knowledgeable sales force in the industry . we are actively seeking to expand our market penetration through increased distribution . to accomplish this , during fiscal year 2014 , for the first time in our history , we made available to all distributors and qualified sales persons , a family of proprietary combination therapy devices , the dynatron 25 series . the availability of these products is attracting new distributors and sales persons . in addition , where these sales persons have had limited or no access to premier lines like the dynatron solarisplus products , they are now able to access these products in certain geographical areas through the authorized sales representative or dealer who has the rights to the products in those territories . making these products more widely available is expected to increase our ability to expand distribution of not only our own proprietary products , but also those we distribute on behalf of other manufacturers . pursuit of national accounts , including group purchasing organizations ( gpo ) continues to be a strategic endeavor . during fiscal year 2014 , we signed an exclusive , sole-source agreement with amerinet , one of the five largest gpo 's in the united states , to supply medical products to their acute care and alternate care members . amerinet is one of the nation 's leading healthcare gpos , helping its members to reduce healthcare costs and improve healthcare quality . the three-year agreement with amerinet became effective july 1 , 2014. the prior vendor reported approximately $ 6,000,000 per year in sales to amerinet members . we do not expect that this contract will rise to that level for various reasons and we anticipate that it will take several months to ramp up sales under this contract . we expect that sales under this contract will gradually increase over the life of the contract to a rate of approximately $ 3,000,000 annually . in 2013 , we were successful in qualifying to be an approved vendor to the federal government , including the veterans administration hospitals and medical facilities associated with military installations . economic pressures from the recent recession in the united states have affected available credit that would facilitate large capital purchases , and have also reduced demand for discretionary services such as those provided by the purchasers of our aesthetic products . as a result , we reduced our expenses in the synergie department . we believe that our aesthetic devices remain the best value on the market and we are seeking innovative ways to market these products , including strategic partnerships , both domestic and international , to help enhance sales momentum . we have long believed that international markets present an untapped potential for growth and expansion . adding new distributors in several countries will be the key to this expansion effort . we remain committed to finding the most effective ways to expand our markets internationally . over the coming year , our efforts will be focused on partnering with key manufacturers and

